# Pizarra — PT-pseudo_376de00c8131 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_376de00c8131
Task: 1

Encounter: Urology - outpatient on 28 Feb 2025.
Referrer: Dr. N. Kuiper (GP).
Type: Re-evaluation - prior negative biopsy.

Clinical data (read-only — values loaded from the record):
  - 52-year-old male
  - PSA: 8.8 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.09 ng/mL²
  - PSA velocity: 0.65 ng/mL/yr
  - Prior PSA: 7.0 ng/mL
  - Prostate volume: 98.0 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Negative (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.61692226 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: Latex
  - Additional notes: PSA 8.8 ng/mL. PI-RADS 4. PSAD 0.09. Prostate volume 98 mL. csPCa 0.62.

Vitals: weight 109 kg, height 192 cm, BMI 29.6, BP 122/78 mmHg, HR 68 bpm. Smoking: Ex-smoker (13 pack-yr, quit 2013).

Chief complaint: Persistent elevation in prostate-specific antigen accompanied by a newly identified PI-RADS 4 lesion on magnetic resonance imaging, documented after a prior negative biopsy.

History: At 52 years of age, he works as a retired secondary school teacher. Initial evaluation in late 2022 focused on a prostate-specific antigen level of 7.1 ng/mL, which led to a systematic biopsy yielding entirely benign results. He is married and maintains an independent household, with his adult son living close by. Physical activity includes cycling roughly 20 kilometres two times each week, while alcohol intake averages 10 units weekly. Lower urinary tract symptoms remain negligible, reflected by an International Prostate Symptom Score of 2 out of 35. He reports no haematuria, pelvic discomfort, or systemic complaints. A 13 pack-year smoking history was concluded in 2013, and he has no known drug allergies beyond latex. Recent routine dental visits continue, and he relies on large-print materials for correspondence due to mild visual impairment. No other significant surgical history or comorbidities are noted, and he takes no active medications.

Physical examination: DRE — texture: smooth and firm; mobility: normal; asymmetry: absent. The prostate presents as symmetrically enlarged without palpable nodules. General inspection reveals a well-nourished individual ambulating independently. Vital signs remain stable, and there is no evidence of abdominal masses or peripheral lymphadenopathy.

Patient info: retired secondary school teacher; Married; Lives alone; adult son nearby.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 10 units / week; exercise Cycling 2x/week, ~20 km; IPSS score: 2/35 (mild LUTS).

Recent other appointments: Dental — biannual check-up.
Admin: Visual impairment: large-print correspondence requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.68 +/- 0.20   (95% CI 0.25-0.97)

Where the uncertainty comes from:
  - aleatoric  dA = 0.17  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.11  (few labelled cases resemble this one)
  - 4.8 effective neighbours out of 10; 5 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {yes}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=4.0, bx_ord=1.0, psa=8.8, age=52.0, psad=0.09, dre_ord=0.0, vol=98.0, n_pmhx=0.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender only used the structured panel. It could not weigh the patient's PSA velocity (0.65 ng/mL/yr) against the prior PSA (7.0 ng/mL) and the current PSA (8.8 ng/mL), which suggests a significant recent rise. It also could not incorporate the specific findings from the mpMRI report (PI-RADS 4 lesion) or the context of the prior negative biopsy, which are critical for risk stratification.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests BIOPSY with a wide interval (0.68 +/- 0.20), indicating high uncertainty. A failure mode is the contradiction between the high csPCa predicted probability (0.61692226) and the prior negative biopsy status. Another failure mode is the DRE being 'Normal' despite a PI-RADS 4 lesion and rising PSA, which might suggest the prior negative biopsy was overly conservative or the current findings are misleading.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <document> radiology / mpMRI report -> If the report details the characteristics/extent of the PI-RADS 4 lesion, it would refine the risk assessment.
  <document> PSA history (trend) -> If the trend shows a rapid increase, it would increase the urgency for intervention.
  <document> previous GP / urology consultation notes -> These notes might contain context regarding the initial negative biopsy or any prior discussions about the PI-RADS 4 finding.
  <document> laboratory results (full panel) -> This could reveal other markers that modify the interpretation of the PSA/PSAD relationship.

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units and dates. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line - that is an honest result.
  
  **radiology / mpMRI report**
  Subject: Multiparametric MRI of the Prostate | Date: 20 February 2025 | Jeroen Bosch Ziekenhuis ('s-Hertogenbosch)
  Clinical context: Elevated prostate-specific antigen (8.8 ng/mL) with re-evaluation after a previously negative biopsy.
  FINDINGS:
  Glandular volume registers at 98.0 mL. T2-weighted sequences highlight a 18 mm focal hypointense area within the peripheral zone of the right mid-gland. Diffusion-weighted imaging exhibits pronounced restricted diffusion, mirrored by corresponding low signal intensity on the apparent diffusion coefficient map. Dynamic contrast-enhanced sequences demonstrate early, focal enhancement confined to the lesion. Seminal vesicles appear normal, with no signs of extracapsular extension or suspicious pelvic lymphadenopathy.
  IMPRESSION:
  PI-RADS 4 lesion in the right mid-gland peripheral zone, measuring approximately 18 mm. PSAD 0.09 ng/mL/mL. csPCa predicted probability 0.61692226.

  **PSA history**
  {"case_id": "PT-pseudo_376de00c8131", "psa_trend": [{"date": "Nov 2022", "val": 7.3}, {"date": "Aug 2023", "val": 7.3}, {"date": "May 2024", "val": 6.5}, {"date": "Feb 2025", "val": 8.8}]}

  **previous GP / urology consultation notes**
  {"date": "07 Sep 2023", "author": "Dr. N. Kuiper (GP)", "text": "07 Sep 2023 - Dr. N. Kuiper (GP): Routine screening captured a PSA level of 6.4 ng/mL, marking a modest decrease from the 7.1 ng/mL recorded in late 2022. Owing to the sustained elevation beyond standard limits and his age, his records were submitted to the urology outpatient clinic to facilitate further diagnostic evaluation and potential imaging."}, {"date": "05 Mar 2024", "author": "Dr. N. Kuiper (GP)", "text": "05 Mar 2024 - Dr. N. Kuiper (GP): Serial testing indicates a gradual PSA ascent, currently at 7.0 ng/mL. Having finished his initial urological workup, he returned for review. In light of the persistent biochemical markers and the requirement for structured surveillance, a follow-up appointment has been arranged to evaluate the most recent imaging and clinical findings."}

  **laboratory results**
  {"name": "PSA", "val": "8.8 ng/mL", "date": "29 Jan 2025", "flag": "H"}, {"name": "Free PSA", "val": "1.72 ng/mL", "date": "29 Jan 2025", "flag": ""}, {"name": "%Free PSA", "val": "20%", "date": "29 Jan 2025", "flag": ""}, {"name": "Haemoglobin", "val": "15.6 g/dL", "date": "29 Jan 2025", "flag": ""}, {"name": "WBC", "val": "7.8 x10^9/L", "date": "29 Jan 2025", "flag": ""}, {"name": "Platelets", "val": "171 x10^9/L", "date": "29 Jan 2025", "flag": ""}, {"name": "Creatinine", "val": "83 umol/L", "date": "29 Jan 2025", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "29 Jan 2025", "flag": ""}, {"name": "Testosterone", "val": "11.7 nmol/L", "date": "29 Jan 2025", "flag": ""}, {"name": "Alkaline phosphatase", "val": "67 U/L", "date": "29 Jan 2025", "flag": ""}, {"name": "LDH", "val": "192 U/L", "date": "29 Jan 2025", "flag": "H"}

NOT RETRIEVED
  get_family_history - Do NOT call this. In this reading form the family-history anamnesis is not part of the biopsy work-up, and a positive or negative first-degree history does not change whether this patient is sampled today.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  PI-RADS 4 lesion in the right mid-gland peripheral zone, measuring approximately 18 mm.
  PSA velocity of 0.65 ng/mL/yr, indicating a significant recent rise (from 6.5 to 8.8 ng/mL over ~1.5 years).
  csPCa predicted probability of 0.61692226.
  
  AGAINST sampling this patient now:
  Prior biopsy was Negative.
  DRE findings are Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done).

WHERE THIS LEANS
  The evidence strongly points towards sampling due to the high-risk MRI finding (PI-RADS 4) and the rising PSA velocity, which contradicts the prior negative biopsy result. This leans towards a strong recommendation for biopsy.

[Sections actually revealed in this consultation: psa_trend, radiology_report, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended because the evidence strongly supports intervention due to a PI-RADS 4 lesion and a rising PSA velocity of 0.65 ng/mL/yr, which contradicts the prior negative biopsy. The decisive factors are the PI-RADS 4 finding and the PSA velocity, which together indicate a significant change in clinical status warranting further tissue sampling.

Variables that carried weight: age=noted, dre=noted, psa=decisive, vol=noted, psad=noted, pirads=decisive
Sections revealed: psa_trend, radiology_report, previous_notes, laboratory_results
